Assertion (A): | In most cases, recombinant therapeutics are safer than similar products isolated from non-human sources. |
Reason (R): | Recombinant therapeutics do not induce unwanted immunological responses. |
1. | Both (A) and (R) are True and (R) correctly explains (A). |
2. | (A) is True but (R) is False. |
3. | Both (A) and (R) are True but (R) does not explain (A). |
4. | Both (A) and (R) are False. |
The first drug produced using recombinant DNA technology is used to treat:
1. | haemophilia | 2. | dwarfism |
3. | immunodeficiency | 4. | diabetes |
1. | A part of mature insulin molecule |
2. | Responsible for formation of disulphide bridges |
3. | Removed during maturation of pro-insulin to insulin |
4. | Responsible for its biological activity |
The main challenge for production of insulin using rDNA techniques was:
1. | to find a suitable host cell that can perform RNA splicing |
2. | isolation of a copy of gene from the human DNA |
3. | getting insulin assembled into a mature form |
4. | downstream processing |
I: | All diabetics require insulin from the very beginning. |
II: | Insulin can be given orally to diabetics. |
III. | Insulin extracted from pancreas of slaughtered cattle and pigs caused some patients to develop allergy. |
IV. | Recombinant insulin was first prepared by Indian pharmaceutical giant Ranbaxy. |
V. | The two polypeptide chains in the final structure of Insulin are joined by disulfide bonds. |
VI. | DNA sequences corresponding to A and B chains of human insulin were introduced in plasmids of E.coli to produce insulin chains for preparing recombinant insulin. |
1. | 2 | 2. | 3 |
3. | 4 | 4. | 5 |